logo
Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections

Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections

Boston Globe14 hours ago

South Shore Health declined to answer questions about whether they were treating suspected cases or how many they were seeing, referring instead to the Department of Public Health.
Advertisement
However Jason Tracy, chief medical officer at the hospital, said generally that patients are given a presumptive diagnosis made off of their clinical presentation of symptoms and history of recent injections.
Related
:
From there, the hospital would involve both the Department of Public Health and the Centers for Disease Control, which has an anti-toxin that it provides on a case-by-case basis. The anti-toxin helps slow the progression of symptoms, but does not reverse them, and so hospitals typically also provide supportive measures.
'This is quite rare,' Tracy said. 'This is different than a food-borne botulism type case. It's not as though there is a lot body of literature to refer clinicians to to give prognosis and historical elements and time courses for what to expect.'
South Shore Hospital in Weymouth.
Pat Greenhouse/Globe Staff
Use of botulinum toxin — commonly known by the popular brand name Botox — for cosmetic procedures is widely
Advertisement
Cosmetic treatments with botulinum toxin use doses much lower than for medical treatments, said Dr. Mathew M. Avram, director of the Mass General Hospital Dermatology Laser and Cosmetic Center.. With regulated, FDA-approved products in a healthy adult, the amount of the toxin is so small that it is exceedingly rare for it to cause botulism.
'I've never seen a patient or had a colleague of mine at Mass General or elsewhere that has told me they have had a case of this. It is not something that happens normally,' Avram said. 'Someone would have to go outside the realm of what you would typically inject to encounter these issues, for a typical patient.'
Beyond injecting far too much, poor administration technique or using counterfeit products can increase risks.
'We have seen instances where injectors have used counterfeit products or products they developed on their own,' Avram said. 'These are unsafe practices that can harm patients.'
According to the advisory, botulism results when the botulinum toxin circulates in the blood. Symptoms including double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, and difficulty breathing. Such symptoms are sometimes followed by muscle weaknesses, which can progress over the course of hours or days.
Advertisement
DPH has asked clinicians to warn patients interested in these cosmetic injections of the potential risks, and is advising patients to receive injections only from licensed providers.
'If someone has had a botox injection and has had those symptoms they should seek medical attention,' Tracy said. 'I don't want to create worry but someone having visual changes, slurred speech and difficulty swallowing — they should not ignore it."
The reports are only the latest Botox problems to surface in the South Shore. In November, 38-year-old Rebecca Fadanelli, was arrested and charged for selling counterfeit Botox out of Skin Beauté Med Spa in Easton and Randolph.
Jessica Bartlett can be reached at

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ProZenith Launches Natural Supplement Formulated for Weight Management Support
ProZenith Launches Natural Supplement Formulated for Weight Management Support

Business Upturn

time3 hours ago

  • Business Upturn

ProZenith Launches Natural Supplement Formulated for Weight Management Support

By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

Yahoo

time4 hours ago

  • Yahoo

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Public health officials confirm new measles case in LA County
Public health officials confirm new measles case in LA County

CBS News

time5 hours ago

  • CBS News

Public health officials confirm new measles case in LA County

Los Angeles County public health officials have confirmed a new measles case in a resident who recently traveled internationally and visited at least three Santa Clarita stores in recent weeks. According to a press release from the Department of Public Health, officials advised that the person visited: the Costco at 18659 Via Princessa from 10 a.m. to noon, the Trader Joes at 19037 Golden Valley Road from 2:30 p.m. to 4 p.m., and the Walmart at 25450, The Old Road, Stevenson Ranch, from 3:15 p.m. to 4:45 p.m. Officials say that other people who came in contact with the person may have been exposed. They advise that symptoms could arise within seven and 21 days, and residents are advised to verify their vaccination status. "Measles is a serious respiratory disease that spreads easily through the air and on surfaces, particularly among people who are not already protected from it," said County Health Officer Dr. Muntu Davis in a statement. "A person can spread the illness to others before they have symptoms, and it can take seven to 21 days for symptoms to show up after exposure. Measles can lead to severe disease in young children and vulnerable adults. The best way to protect yourself and your family from infection is with the highly effective measles vaccine." According to health officials, measles symptoms can include fever, cough, runny nose, red eyes and fatigue. People typically notice a red rash one to four days after symptoms first start, beginning on the head and then spreading to the lower body. This is now at least the 13th case of measles confirmed in California thus far this year, according to the California Department of Public Health. The first Los Angeles County case was reported back in March, however in February officials also noted that an Orange County infant with the disease traveled through LAX.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store